noom glp 1 dosage chart Customized Compounded GLP-1 Weight Loss Plans GLP-1 Microdosing 2026: 0.1mg Chart

Approval timelines, system glitches, and any growing pains are largely outside of our practices control

GLP-1 medications generally aren't appropriate with: Personal/family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia type 2 (MEN 2) History of pancreatitis Severe gastroparesis or GI motility disorders Pregnancy, trying to conceive, or breastfeeding A history of eating disorders (requires careful evaluation) Josh reviews your full history at your consult to confirm treatment is safe for you

Annals of Internal Medicine DOI:10.7326/ANNALS-25-00860 Abstract Glucagon-Like Peptide-1 Receptor Agonists and Risk for Ischemic Optic Neuropathy: A Target Trial Emulation Background: There are few data evaluating the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and nonarteritic anterior ischemic optic neuropathy (NAION), which constitutes approximately 75% of ischemic optic neuropathy (ION) cases in adults

That doesnt mean theyre unsafe it just means that like any medical decision, its about weighing what we know against what we dont, and deciding what makes sense for you